Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study.

Publication Year: 2022

DOI:
10.1111/bcp.15232

PMCID:
PMC9303426

PMID:
35028950

Journal Information

Full Title: Br J Clin Pharmacol

Abbreviation: Br J Clin Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"COMPETING INTERESTS Michel J.A.M. van Putten is co‐founder of Clinical Science Systems, Leiden, The Netherlands. All other authors declare no conflict of interest."

Evidence found in paper:

"Funding information Stichting Life Sciences Holland (LSH) ‐ TKI, Health~Holland, under LSH Match, Grant/Award Number: LSHM16055‐SGF"

Evidence found in paper:

"This study was approved by the Ethics Committee Stichting Beoordeling Ethiek Biomedisch Onderzoek, Assen, The Netherlands. The trial was executed in accordance to the Declaration of Helsinki at the Centre for Human Drug Research (CHDR), Leiden, The Netherlands, between September 2017 and February 2018. The study is registered in the Dutch Trial Registry (NTR) under NL6638."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025